Bumetanide considered effective in the treatment of genetic Alzheimer's by the end of 2026?
Salud y medicinaOne-Off2m
FutuurComprobar disponibilidadDatos de resolución verificadosProbabilidad implícita actual
No 93%
No 93%Calidad del mercado
31 / 100
Baja calidadVolumen 24h
—
Liquidez
230,2 €
Baja liquidezTraders
9
Comentarios
1
Datos de mercado
Actualizado hace 1 minuto
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will cold showers be shown to be an effective treatment for depression by 2030
Manifold MarketsWhen will the FDA reclassify BPC-157 to Category 1?
KalshiEbola pandemic in 2026?
PolymarketHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiReglas
Drug repositioning is a common technique in research, where drugs that have already been approved to treat a certain disease are used to treat different diseases.
- By cross-referencing information from various sources, scientists in the United States have arrived at a drug that might be repositioned to treat Alzheimer's disease in patients with genetic mutations that increase the risk of developing the disease.
- According to their studies, Bumetanide - a diuretic drug - managed to reduce learning deficits in mice, and showed positive effects in human neurons in vitro.
- The next step was to analyze the medical records of more than 5 million adult patients, which led to the observation that the development of Alzheimer's disease was lower among those who made use of the diuretic drug.
- Despite the encouraging news, more tests are still needed to validate such a hypothesis.
- The next step for researchers will be to conduct randomized clinical trials to demonstrate the efficacy of bumetanide against genetic Alzheimer's disease.